Fig. 6: Validating expression of SLC25A5 and SLC25A24 in clinical specimens of colon cancer. | Cell Death & Disease

Fig. 6: Validating expression of SLC25A5 and SLC25A24 in clinical specimens of colon cancer.

From: An integrated bioinformatic investigation of mitochondrial solute carrier family 25 (SLC25) in colon cancer followed by preliminary validation of member 5 (SLC25A5) in tumorigenesis

Fig. 6

A Immunofluorescence was used to determine the location of SLC25A5 and SLC25A24 in colon cancer-derived HCT116 and RKO cells. B Immunohistochemical examinations suggested that the expression levels of SLC25A5 (n = 72) and SLC25A24 (n = 76) were lower in colon cancer tissues than in adjacent normal tissues in patients receiving radical surgery resection. C Kaplan–Meier survival curves suggested that patients with upregulated SLC25A5 (HR = 0.33, p < 0.05) and SLC25A24 (HR = 0.47, p < 0.05) experienced a longer survival time after surgical treatment. D Spearman correlation analyses suggested that the expression of SLC25A5 negatively correlated with that of CD8 (Spearman r = −0.27, p < 0.05), while the expression of SLC25A24 positively correlated with that of CD19 (Spearman r = 0.21, p < 0.05). Scale bars are 20 μm in (A) and 50 μm or 200 μm in (B). Statistical analysis: Student’s T test, **p < 0.01, ***p < 0.001.

Back to article page